---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112975"
form_type: "8-K/A"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:51:52.688534+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80

## Summary
- Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).
- Q3 revenue $976M (+7% reported, +6% organic); CAG Diagnostics recurring revenue +7%.
- Q3 diluted EPS $2.80, +11% as reported, +12% comparable basis; operating margin 31.2%.
- Updated FY24 revenue guidance to $3.865B-$3.890B (~1% lower at midpoint); EPS narrowed to $10.37-$10.53.
- FY24 organic revenue growth now 5.3%-6.0% (prior 6.2%-7.8%) due to softer U.S. clinic visit trends.

## SEC filing metadata
- accession: 0001104659-24-112975
- form_type: 8-K/A
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465924112975/0001104659-24-112975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465924112975/tm2427217d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112975
- JSON: https://secwatch.observer/filing/0001104659-24-112975.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.